Amarin's (NASDAQ: AMRN) Vascepa is the only fish oil supplement approved by the FDA to treat anything, and sales have been soaring since the company presented evidence that it can prevent heart attacks for millions of high-risk patients. On Tuesday, the company announced preliminary 2019 results, and as expected, Vascepa sales growth was impressive.
In 2019, Vascepa sales grew around 85% compared to 2018, coming in between $410 million and $425 million. And the company thinks 2020 will be much better. That's a fairly simple prediction to make because, in December, the Food and Drug Administration approved Vascepa to prevent patients at risk of a second heart attack from having one.
Image source: Getty Images.